AB is a 17-year-old girl who has migraines with aura and presents for contraceptive management. Based on the US Medical Eligibility Criteria for Contraceptive Use, estrogen-containing contraceptives are contraindicated for AB due to an elevated risk of thrombosis given her diagnosis of migraines with aura. After determining which contraceptive methods are safe, comprehensive counseling should start with a discussion of the most effective contraceptive methods including intrauterine devices (IUDs) and subdermal contraceptive implants. AB elects to have an IUD placed which is inserted the same day given it is reasonably certain she is not pregnant and no sedation is required prior to IUD placement. The only mandatory examination needed prior to IUD placement is a bimanual examination and cervical inspection in accordance with the US Selected Practice Recommendations for Contraceptive Use. Finally, condom use at every sexual encounter is recommended to reduce the risk for sexually transmitted infections.
KeywordsContraceptive agents Female Long-acting reversible contraceptive Intrauterine device Contraceptive implant Adolescent health Reproductive health
- 3.Centers for Disease Control and Prevention. Summary chart of U.S. medical eligibility criteria for contraceptive use. 2016. Available via CDC. http://www.cdc.gov/reproductivehealth/contraception/pdf/summary-chart-us-medical-eligibility-criteria_508tagged.pdf. Accessed 29 July 2016.
- 6.Beksinska ME, Smit JA, Kleinschmidt I, et al. Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, non-users and discontinuers of hormonal contraception. Contraception. 2010;81(1):30–4. https://doi.org/10.1016/j.contraception.2009.07.007.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Centers for Disease Control and Prevention. Providing quality family planning services: recommendations of CDC and the U.S. Office of Population Affairs. MMWR. 2014;63(RR-04):1–54.Google Scholar
- 12.American College of Obstetricians and Gynecologists. ACOG committee opinion no. 554: reproductive and sexual coercion. Obstet Gynecol. 2013;121:411–5. https://doi.org/10.1097/01.AOG.0000426427.79586.3b.CrossRefGoogle Scholar
- 13.Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, et al., editors. Contraceptive technology. 18th ed. New York: Ardent Media, Inc.; 2004.Google Scholar
- 21.Eisenberg DL, Schreiber CA, Turok DK, et al. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception. 2015;92(1):10–6. https://doi.org/10.1016/j.contraception.2015.04.006.CrossRefPubMedGoogle Scholar
- 23.Lopez LM, Bernholc A, Zeng Y, et al. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev. 2015;(7):CD007373. doi:https://doi.org/10.1002/14651858.CD007373.pub3.
- 31.Maddox DD, Rahman Z. Etonogestrel (Implanon), another treatment option for contraception. Drug Forecast. 2008;33(6):337–47.Google Scholar
- American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 642: increasing access to contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol. 2015;126(412-417):44–8.Google Scholar
- Centers for Disease Control and Prevention. Effectiveness of family planning methods. 2010. Available at https://www.cdc.gov/reproductivehealth/unintendedpregnancy/pdf/contraceptive_methods_508.pdf. Accessed 20 July 2016.
- Centers for Disease Control and Prevention. Summary chart of U.S. medical eligibility criteria for contraceptive use. 2016. Available at http://www.cdc.gov/reproductivehealth/contraception/pdf/summary-chart-us-medical-eligibility-criteria_508tagged.pdf. Accessed 29 July 2016.
- Guttmacher Institute. An overview of minors’ consent law as of March 1, 2016. State Policies in Brief. 2016. Available at https://www.guttmacher.org/sites/default/files/pdfs/spibs/spib_OMCL.pdf. Accessed 2 Aug 2016.